

August 6, 2007

Indevus Announces FDA Approval of Sanctura® XR

August 6, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Sanctura® XR (trospium chloride extended release capsules) has been approved by the U.S. Food and Drug Administration (FDA).

CONTACT:

Russell "Rip" Wilson Chief Financial Officer Supernus Pharmaceuticals, Inc.

Tel: 301 838-2522

All trademarks are the property of their respective owners.